Cigna Corporation
CI
NYSE·Healthcare·Medical - Healthcare Plans·Mkt cap $74.8B
$283.06
▲ +2.53%
P/E
11.72
Mkt Cap
$74.8B
52-Wk Range
$239.51–$315.47
52-Week Range
$239.51 - $315.47
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 5.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive Provider Network
- Advanced Healthcare Analytics
- Comprehensive Service Integration
- Strong Brand Recognition
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Medicare Market Expansion
Value
Deep value opportunity - significant discount to Managed Care & Health Insurance peers
Momentum
Stable
+3.8% over 3m
Quality
Thin
Excellent business quality
Dividend
Solid
2.17% yield
Smart-money signal
Who's buying CI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of $7.78 vs $7.60 consensus (+2.4% surprise). Revenue of $71.7B vs $70.1B expected (+2.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2.4%
Revenue trend · last 8Q
—
+28%
+14%
+11%
+10%
+10%
+5%
+7%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$63.7B
$65.6B
$65.5B
$67.2B
$69.7B
$72.5B
$68.5B
$71.7B
Margins · last 8Q
Gross
0.0%
Operating
0.0%
Profit
2.3%
Wall Street consensus
14 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
29%
Sell
21%
Median Price Target
—
Latest: Jefferies · Aug 4, 2026
vs Industry
How CI stacks vs Medical - Healthcare Plans
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related